suPARnostic® is the only CE-IVD certified product range applied for clinical determination of suPAR in human plasma and serum.

suPAR is a universal and broadly applicable prognostic biomarker of chronic inflammation and immune activation across diseases. suPAR can identify inflammation and immune activation to aid in determining the risk of patient outcomes.

Significant clinical benefits include:

• Identification of patients who can be safely discharged after treatment
• Helps to prioritize patients and reduce Emergency Department crowding
• Add to clinical decisions
• Identification of high-risk patients with unaffected vital signs

suPARnostic® also improves the efficiency of the Emergency Department by shortening the average patient-length-of-stay, which leads to cost savings.